At Telomir Pharmaceuticals, we are focused on understanding disease at its most fundamental level — and developing therapies designed to intervene there.

Our lead program, Telomir-Zn, targets the disruption of iron and copper balance inside cells, a mechanism implicated in the epigenetic dysregulation that drives cancer cell survival and treatment resistance. The program has received FDA clearance to begin Phase 1/2 clinical trials in triple-negative breast cancer (TNBC).

We are committed to science that goes beyond managing symptoms — targeting the upstream biology that matters.